Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,328 active trials222 approved drugs2,775 evidence items
- NCIt
- C4741
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,686 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06672146 | Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial) | recruiting | Phase 2 | 93 | National Cancer Institute (NCI)NIH | 2 | Sep 22, 2026 | clinicaltrials |
| NCT06712316 | Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer | recruiting | Phase 2 / Phase 3 | 1,580 | BioNTech SEINDUSTRY | 22 | Sep 22, 2026 |
| NCT06814496 | Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors(RABBIT) | recruiting | Phase 1 / Phase 2 | 30 | University of ArizonaOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06863311 | Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC(EXACT) | recruiting | Phase 2 | 70 | Karie RuncieOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06875310 | A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) | recruiting | Phase 3 | 630 | Mirati Therapeutics Inc.INDUSTRY | 35 | Sep 22, 2026 | clinicaltrials |
| NCT07006727 | Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors | recruiting | Phase 1 | 116 | Novartis PharmaceuticalsINDUSTRY | 4 | Sep 22, 2026 | clinicaltrials |
| NCT07028489 | Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer | recruiting | — | 130 | N-Power MedicineINDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07060261 | Pre-Op MRI on Margin Status for Transoral Robotic Surgery for HPV+ Tonsillar Squamous Cell Carcinoma | recruiting | N/A | 30 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07100080 | Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) | recruiting | Phase 2 / Phase 3 | 500 | Bristol-Myers SquibbINDUSTRY | 25 | Sep 22, 2026 | clinicaltrials |
| NCT07101328 | A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )(BAF_FRontier-1) | recruiting | Phase 1 | 215 | Eli Lilly and CompanyINDUSTRY | 12 | Sep 22, 2026 | clinicaltrials |
| NCT07104630 | Pulmonary Rehabilitation in Advanced Lung Cancer Survivors | recruiting | Phase 2 | 85 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07146646 | Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer | recruiting | Phase 2 | 27 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07174388 | An External Control Arm Study in Non-Small Cell Lung Cancer | recruiting | — | 650 | N-Power MedicineINDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07186699 | Qualitative Study on Detection & Tx of NSCLC in Pts w/ a History of Alcohol or SUD | recruiting | — | 45 | University of Southern CaliforniaOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07213674 | A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer | recruiting | Phase 3 | 750 | AmgenINDUSTRY | 18 | Sep 22, 2026 | clinicaltrials |
| NCT07213791 | A Study of LY4337713 in Participants With FAP-Positive Solid Tumors(FiREBOLT) | recruiting | Phase 1 | 241 | Eli Lilly and CompanyINDUSTRY | 5 | Sep 22, 2026 | clinicaltrials |
| NCT07218341 | A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | recruiting | Phase 4 | 150 | Eli Lilly and CompanyINDUSTRY | 17 | Sep 22, 2026 | clinicaltrials |
| NCT07218380 | A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract(FORAGER-2) | recruiting | Phase 3 | 450 | Eli Lilly and CompanyINDUSTRY | 19 | Sep 22, 2026 | clinicaltrials |
| NCT07226843 | A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers | recruiting | Phase 1 | 460 | Eli Lilly and CompanyINDUSTRY | 8 | Sep 22, 2026 | clinicaltrials |
| NCT07278479 | Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors | recruiting | Phase 1 / Phase 2 | 138 | Molecular Partners AGINDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07409272 | A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer | recruiting | Phase 3 | 614 | Astellas Pharma Global Development, Inc.INDUSTRY | 6 | Sep 22, 2026 | clinicaltrials |
| NCT07488676 | A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors | recruiting | Phase 1 / Phase 2 | 150 | Astellas Pharma Global Development, Inc.INDUSTRY | 2 | Sep 22, 2026 | clinicaltrials |
| NCT07522476 | A Clinical Study to Evaluate the Efficacy and Safety of VG2025 in Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 30 | Virogin Biotech Ltd.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07565740 | Intranasal WSK-IM05 Vaccine Plus Tislelizumab as Neoadjuvant Therapy for HPV+ OPSCC | recruiting | Phase 1 | 9 | West China HospitalOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07570979 | A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer | recruiting | Phase 1 | 208 | Novartis PharmaceuticalsINDUSTRY | 6 | Sep 22, 2026 | clinicaltrials |
| NCT07614620 | Effect of Hypnosis in the Management of Anxiety and Chemo-induced Symptoms in Adolescents and Young Adults With Sarcoma or Germ Cell Tumor and in Young Women With Breast Cancer(HYPNO-AJA2) | recruiting | N/A | 70 | Institut BergoniéOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07619521 | Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07661095 | A Study of CRD3874-SI in People With Leukemia | recruiting | Phase 1 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07728019 | Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM | recruiting | Phase 2 | 60 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07801508 | A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors | recruiting | Phase 1 | 66 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07824349 | JUR-003 in Adult Patients With Metastatic Prostate Cancer | recruiting | Phase 1 | 210 | Juri Biosciences, Inc.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07835035 | Rimegepant Plus Toripalimab in Advanced Urothelial Carcinoma After Failure of Standard Therapy | recruiting | Phase 1 | 12 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07835087 | Image-Guided Platform-Assisted Sentinel Lymph Node Retrieval in Early Gastric Cancer | recruiting | N/A | 36 | Beijing Friendship HospitalOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT02620852 | Women Informed to Screen Depending on Measures of Risk (Wisdom Study)(WISDOM) | recruiting | N/A | 100,000 | University of California, San FranciscoOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT03909412 | Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma(CarMob) | recruiting | Phase 1 | 18 | Hackensack Meridian HealthOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04084730 | Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer | recruiting | Phase 2 | 280 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04523428 | REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL) | recruiting | Phase 2 | 60 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 3 | Sep 21, 2026 | clinicaltrials |
| NCT04661137 | A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma | recruiting | Phase 2 | 96 | Hackensack Meridian HealthOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04935684 | Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation(TMF-Allo) | recruiting | Phase 2 | 150 | University Hospital, Clermont-FerrandOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04977375 | Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma | recruiting | Phase 1 / Phase 2 | 10 | Chirag G. PatilOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05008848 | Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program | recruiting | Phase 3 | 600 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05296070 | Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma | recruiting | Phase 2 | 50 | University of MiamiOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05521412 | EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T(VIOLET) | recruiting | Phase 1 / Phase 2 | 66 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05550415 | The Role of Simvastatin in The Epithelial-Mesenchymal Transition Process of Breast Cancer | recruiting | Phase 2 | 26 | Universitas IndonesiaOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05578326 | Study of Trilaciclib and Lurbinectidin | recruiting | Phase 2 | 30 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05983432 | Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors | recruiting | Phase 1 | 540 | SystImmune Inc.INDUSTRY | 5 | Sep 21, 2026 | clinicaltrials |
Data updated 6 days agoSource updated Sep 22, 2026source: clinicaltrials